Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients

The standard of care in the management of immune-mediated inflammatory conditions relies on immunomodulators, glucocorticoids, and biologicals (including anti-tumour necrosis factor −α and other monoclonal antibodies). These agents have an overall favourable benefit/risk ratio; however, they modulate the immune response as part of their mechanisms of action, and therefore they may increase the risk of developing infections, particularly in older patients or in patients with concomitant corticosteroids.

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2wXiGGW
via IFTTT